MCID: PRL003
MIFTS: 44

Proliferative Glomerulonephritis

Categories: Nephrological diseases

Aliases & Classifications for Proliferative Glomerulonephritis

MalaCards integrated aliases for Proliferative Glomerulonephritis:

Name: Proliferative Glomerulonephritis 12 54 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:4778
NCIt 49 C35281
UMLS 71 C0235618

Summaries for Proliferative Glomerulonephritis

MalaCards based summary : Proliferative Glomerulonephritis is related to acute proliferative glomerulonephritis and mesangial proliferative glomerulonephritis. An important gene associated with Proliferative Glomerulonephritis is CXCL9 (C-X-C Motif Chemokine Ligand 9), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Azathioprine and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include kidney, t cells and b cells, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Proliferative Glomerulonephritis

Diseases in the Proliferative Glomerulonephritis family:

Acute Proliferative Glomerulonephritis

Diseases related to Proliferative Glomerulonephritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 420)
# Related Disease Score Top Affiliating Genes
1 acute proliferative glomerulonephritis 34.9 MPO CCL2 C3
2 mesangial proliferative glomerulonephritis 32.0 THY1 TGFB1I1 PDGFD IL6 EDN1 CCR5
3 glomerulonephritis 30.9 MPO CR1 CFH CD55 CCN2 CCL2
4 cryoglobulinemia 30.8 IL6 IFNG CXCR3 CXCL10
5 c3 glomerulopathy 30.8 CFH C3
6 dense deposit disease 30.8 CFH C3
7 purpura 30.8 IL6 IL4 C3
8 vasculitis 30.6 MPO IL6 CCL2 C3
9 relapsing polychondritis 30.5 IL6 IFNG CCL2
10 crescentic glomerulonephritis 30.5 MPO CCR5 CCN2 CCL2
11 genetic atypical hemolytic-uremic syndrome 30.4 CFH C3
12 pyelonephritis 30.3 IL6 IFNG CXCL10 CCL2
13 hemolytic-uremic syndrome 30.3 CFH CD55 C3
14 lymphadenitis 30.2 IFNG CXCR3 CXCL9
15 bacterial infectious disease 30.1 IL6 IFNG CXCL9 CCL2
16 aphthous stomatitis 30.1 IL6 IL4 IFNG
17 leprosy 3 30.1 IL6 IL4 IFNG CXCL10
18 temporal arteritis 30.1 MPO IL6 IFNG CCL2
19 hepatitis a 30.1 IL4 IFNG CXCL10
20 immune-complex glomerulonephritis 30.0 MPO CCR5 CCR1
21 hemolytic uremic syndrome, atypical 1 30.0 CR1 CFH CD55 C3
22 crohn's disease 29.9 IL6 IL4 IFNG CCL2
23 peripheral nervous system disease 29.9 IL6 IL4 IFNG CCL2
24 kidney disease 29.9 IL6 EDN1 CFH CCN2 CCL2 C3
25 hemoglobinuria 29.9 CR1 CD55 C3
26 retinal detachment 29.9 IL6 IFNG CCN2 CCL2
27 aspergillosis 29.9 IL6 IL4 IFNG CXCL10
28 castleman disease 29.9 IL6 IL4 IFNG CR1
29 schistosomiasis 29.9 IL4 IFNG CCL2
30 hemolytic anemia 29.8 CR1 CFH CD55 C3
31 q fever 29.8 IL6 IL4 IFNG CXCL9 CCL2
32 pancytopenia 29.8 MPO IL6 IFNG CD55
33 lymphopenia 29.7 IL6 IL4 IFNG CD55
34 myasthenia gravis 29.7 IL4 IFNG CR1 CD55
35 osteomyelitis 29.7 IL6 IL4 IFNG CXCL10 CCL2
36 proteasome-associated autoinflammatory syndrome 1 29.6 MPO IL6 IL4 IFNG CXCL10 CCL2
37 myocarditis 29.5 IL6 IL4 IFNG CD55 CCL2
38 systemic scleroderma 29.3 IL6 IL4 IFNG EDN1 CCN2
39 respiratory failure 29.3 MPO IL6 EDN1 CXCL10
40 psoriasis 29.2 IL6 IL4 IFNG CXCR3 CXCL9 CXCL10
41 interstitial lung disease 29.2 IL6 IL4 IFNG EDN1 CXCL9 CXCL10
42 leukemia, chronic lymphocytic 29.1 IL6 IL4 CXCR3 CR1 CD55 CCR5
43 uveitis 29.1 IL6 IL4 IFNG CXCR3 CXCL10 CCR5
44 connective tissue disease 29.0 IL6 IL4 IFNG EDN1 CCN2 CCL2
45 autoimmune disease 29.0 IL6 IL4 IFNG CXCR3 CD55 CCR5
46 trypanosomiasis 29.0 IL6 IL4 IFNG CXCR3 CXCL9 CXCL10
47 chronic kidney disease 28.9 IL6 EDN1 CCR5 CCN2 CCL2
48 arteriosclerosis 28.7 IL6 IL4 IFNG EDN1 CXCR3 CCR5
49 behcet syndrome 28.5 MPO IL6 IL4 IFNG CCR5 CCR1
50 pulmonary disease, chronic obstructive 28.4 MPO IL6 IL4 CXCR3 CXCL10 CCR5

Graphical network of the top 20 diseases related to Proliferative Glomerulonephritis:



Diseases related to Proliferative Glomerulonephritis

Symptoms & Phenotypes for Proliferative Glomerulonephritis

MGI Mouse Phenotypes related to Proliferative Glomerulonephritis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.25 C3 CCN2 CCR1 CCR5 CFH CXCL10
2 homeostasis/metabolism MP:0005376 10.2 C3 CCN2 CCR1 CCR5 CFH CXCL10
3 hematopoietic system MP:0005397 10.15 C3 CCR1 CCR5 CD55 CFH CXCL10
4 immune system MP:0005387 10.03 C3 CCL2 CCR1 CCR5 CFH CXCL10
5 digestive/alimentary MP:0005381 10.01 C3 CCN2 CCR1 CCR5 EDN1 IFNG
6 muscle MP:0005369 9.76 C3 CCR5 CFH EDN1 IFNG IL6
7 normal MP:0002873 9.61 C3 CCN2 CFH CXCR3 EDN1 IFNG
8 renal/urinary system MP:0005367 9.23 C3 CCR1 CFH CXCR3 EDN1 IFNG

Drugs & Therapeutics for Proliferative Glomerulonephritis

Drugs for Proliferative Glomerulonephritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 3 446-86-6 2265
2
Mycophenolic acid Approved Phase 2, Phase 3 24280-93-1 446541
3
Abatacept Approved Phase 2, Phase 3 332348-12-6 10237
4
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
5
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
6
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
7
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
8 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
9
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
10
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
11 Antimetabolites Phase 3
12 Immunosuppressive Agents Phase 2, Phase 3
13 Anti-Infective Agents Phase 2, Phase 3
14 Antitubercular Agents Phase 2, Phase 3
15 Antibiotics, Antitubercular Phase 2, Phase 3
16 Immunologic Factors Phase 2, Phase 3
17 Anti-Bacterial Agents Phase 2, Phase 3
18 Antirheumatic Agents Phase 2, Phase 3
19 Methylprednisolone Acetate Phase 2, Phase 3
20 Pharmaceutical Solutions Phase 2, Phase 3
21 Hormone Antagonists Phase 2, Phase 3
22 Anti-Inflammatory Agents Phase 2, Phase 3
23 glucocorticoids Phase 2, Phase 3
24 Antineoplastic Agents, Hormonal Phase 2, Phase 3
25 Hormones Phase 2, Phase 3
26 Daratumumab Approved Phase 2 945721-28-8
27 Antibodies, Monoclonal Phase 2
28 Immunoglobulins Phase 2
29 Antibodies Phase 2
30
Tacrolimus Approved, Investigational Phase 1 104987-11-3 445643 439492 6473866
31
Triamcinolone Approved, Vet_approved Phase 1 124-94-7 31307
32
tannic acid Approved Phase 1 1401-55-4
33
Benzocaine Approved, Investigational Phase 1 1994-09-7, 94-09-7 2337
34
Hydrocortisone acetate Approved, Vet_approved Phase 1 50-03-3
35
Acetaminophen Approved Phase 1 103-90-2 1983
36
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
37
Hydrocortisone Approved, Vet_approved Phase 1 50-23-7 5754
38
Diphenhydramine Approved, Investigational Phase 1 147-24-0, 58-73-1 3100
39
alemtuzumab Approved, Investigational Phase 1 216503-57-0
40
Fludarabine Approved Phase 1 21679-14-1, 75607-67-9 30751
41
Promethazine Approved, Investigational Phase 1 60-87-7 4927
42 Alkylating Agents Phase 1
43 Triamcinolone hexacetonide Phase 1
44 triamcinolone acetonide Phase 1
45 Triamcinolone diacetate Phase 1
46 Calcineurin Inhibitors Phase 1
47 Hydrocortisone hemisuccinate Phase 1
48 Antineoplastic Agents, Immunological Phase 1
49 Hydrocortisone 17-butyrate 21-propionate Phase 1
50 diuretics Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Randomized Multicenter Trial Comparing Mycophenolate Mofetil and Azathioprine as Remission-maintaining Treatment for Proliferative Lupus Glomerulonephritis. The MAINTAIN Nephritis Trial. Completed NCT00204022 Phase 3 Mycophenolate mofetil;Azathioprine
2 A Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids in Subjects With Active Proliferative Glomerulonephritis Due to Systemic Lupus Erythematosus (SLE) Terminated NCT00430677 Phase 2, Phase 3 Corticosteroids (prednisone or prednisolone);Abatacept;Abatacept;Mycophenolate mofetil (MMF);Abatacept
3 Immune Ablation and Hematopoietic Stem Cell Support in Patients With Poor Prognostic Indicators and Systemic Lupus Erythematosus:A Phase II Study Completed NCT00271934 Phase 2
4 Single-center Phase 2 Open-label Trial Evaluating Efficacy and Safety of Daratumumab in Treatment of Patients With Proliferative Glomerulonephritis With Monoclonal Immune Deposits and C3 Glomerulopathy Associated With Monoclonal Gammopathy Recruiting NCT03095118 Phase 2 Daratumumab
5 Tacrolimus Versus Cyclophosphamide as Treatment for Diffuse Proliferative or Membranous Lupus Nephritis: Prospective Cohort Study Completed NCT01207297 Phase 1 Tacrolimus;cyclophosphamide
6 Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation for Severe Autoimmune Diseases Terminated NCT00849745 Phase 1
7 A Randomized Multicenter Trial Comparing Leflunomide and Azathioprine as Remission-Maintaining Treatment for Proliferative Lupus Glomerulonephritis. Unknown status NCT01172002 Leflunomide;Azathioprine
8 Clinical Significance of Assesment of Serum miRNA-30a in Childhood Nephrotic Syndrome Unknown status NCT03235128

Search NIH Clinical Center for Proliferative Glomerulonephritis

Genetic Tests for Proliferative Glomerulonephritis

Anatomical Context for Proliferative Glomerulonephritis

MalaCards organs/tissues related to Proliferative Glomerulonephritis:

40
Kidney, T Cells, B Cells, Monocytes, Liver, Endothelial, Lung

Publications for Proliferative Glomerulonephritis

Articles related to Proliferative Glomerulonephritis:

(show top 50) (show all 2389)
# Title Authors PMID Year
1
[Expression of MCP-1 in renal tissues of patients with IgA nephropathy]. 54 61
19893256 2009
2
Characterization of kidney lesions in Indian adults: towards a renal biopsy registry. 54 61
16736422 2006
3
IP-10 and Mig production by glomerular cells in human proliferative glomerulonephritis and regulation by nitric oxide. 54 61
11752021 2002
4
High endothelial venule-like vessels in the interstitial lesions of human glomerulonephritis. 54 61
11919403 2002
5
Renal involvement in Adamantiades-Behçet's disease. Case report and review of the literature. 54 61
11760401 2001
6
Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis. 54 61
10589690 1999
7
Successful treatment of adult-onset Henoch-Schönlein purpura nephritis with high-dose immunoglobulins. 54 61
10361914 1999
8
Significance of P-selectin expression in human glomerulonephritis. 54 61
9594207 1997
9
Increased mRNA expression of metalloproteinase-9 in peripheral blood monocytes from patients with immunoglobulin A nephropathy. 54 61
8712219 1996
10
Increased sMer, but not sAxl, sTyro3, and Gas6 relate with active disease in juvenile systemic lupus erythematosus. 61
31655933 2020
11
Successful simultaneous liver-kidney transplantation for renal failure associated with hereditary complement C3 deficiency. 61
31970896 2020
12
HHV-8-negative multicentric Castleman disease presenting as a crescentic immune complexes membranoproliferative glomerulonephritis. 61
31911409 2020
13
Case report on mesangial proliferative glomerulonephritis with multicentric Castleman's disease: Approach to the onset mechanism of immunoglobulin A nephropathy. 61
31978558 2020
14
Macrophage migration inhibitory factor regulates integrin-β1 and cyclin D1 expression via ERK pathway in podocytes. 61
31986415 2020
15
Multiparameter Flow Cytometry for the Identification of Neoplastic Plasma Cells in POEMS Syndrome with IgG-kappa Gammopathy: Successful Treatment Using Lenalidomide and Dexamethasone. 61
31391391 2019
16
Epidemiological and clinical characteristics and outcome of monoclonal gammopathy of renal significance-related lesions in Latin America. 61
31825549 2019
17
TGF-β1 inhibits the autophagy of podocytes by activating mTORC1 in IgA nephropathy. 61
31600491 2019
18
Bevacizumab-induced immunoglobulin A vasculitis with nephritis: A case report. 61
31702653 2019
19
Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone. 61
32001067 2019
20
[Acute renal failure and rare severe complication of systemic steroid treatment in a 73-year-old woman]. 61
31511906 2019
21
Prevention of parvovirus B19-induced repetitive acute kidney failure by subcutaneous immunoglobulins. 61
31605404 2019
22
The effectiveness of chitosan-mediated silencing of PDGF-B and PDGFR-β in the mesangial proliferative glomerulonephritis therapy. 61
31265815 2019
23
HIV-associated Immune Complex Kidney Disease with C3-dominant Deposition Induced by HIV Infection after Treatment of IgA Nephropathy. 61
31243235 2019
24
Clinicopathologic Assessment of Monoclonal Immunoglobulin-Associated Renal Disease in the Kidney Allograft. A Retrospective Study and Review of the Literature. 61
31634325 2019
25
Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits without Conspicuous Mesangial Proliferation, Complicated with Squamous Cell Lung Carcinoma. 61
31611527 2019
26
Nephrotic syndrome: immunological mechanisms. 61
31630708 2019
27
Monoclonal Gammopathy of Renal Significance and its Associated Experimental Models. 61
31471332 2019
28
PC-1 NF suppresses high glucose-stimulated inflammation and extracellular matrix accumulation in glomerular mesangial cells via the Wnt/β-catenin signaling. 61
31410160 2019
29
The role of transcriptional factor D-site-binding protein in circadian CCL2 gene expression in anti-Thy1 nephritis. 61
29568121 2019
30
Chronological change of renal pathological findings in the proliferative glomerulonephritis with monoclonal IgG deposits considered to have recurred early after kidney transplantation. 61
30805792 2019
31
Urine macrophages reflect kidney macrophage content during acute tubular interstitial and glomerular injury. 61
31212026 2019
32
Renal pathologic spectrum and clinical outcome of monoclonal gammopathy of renal significance: A large retrospective case series study from a single institute in China. 61
31301197 2019
33
Diagnostic Value of Urinary miR-152-5p in Patients with IgA Nephropathy with Elevated Proteinuria Levels. 61
31307184 2019
34
Membranoproliferative glomerulonephritis with deposition of monoclonal IgG evolved from polyclonal IgG: a case report with two consecutive renal biopsies. 61
31331283 2019
35
Case of immunotactoid glomerulopathy showing high responsiveness to steroids therapy despite severe pathological features. 61
31350228 2019
36
Recurrent Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits in Kidney Allografts Treated With Anti-CD20 Antibodies. 61
30747850 2019
37
Clinicopathologic correlations of renal biopsy findings from northeast China: A 10-year retrospective study. 61
31169695 2019
38
Renal histopathology of prolonged acute kidney injury in HELLP syndrome: a case series and literature review. 61
30989562 2019
39
Successful Treatment for BK Virus Nephropathy by Leflunomide in a Kidney Transplant Patient: A Case Report. 61
31084921 2019
40
Clinical significance of C4d deposition in renal tissues from patients with primary Sjögren's syndrome-a preliminary study. 61
31138153 2019
41
Postinfectious Glomerulonephritis with Crescents in an Elderly Diabetic Patient after Acute Gastroenteritis: Case Report. 61
31192229 2019
42
Performance of the Automated Urinalysis in Diagnosis of Proliferative Glomerulonephritis. 61
31080928 2019
43
Head and Neck Manifestations of Granulomatosis with Polyangiitis: A Retrospective analysis of 19 Patients and Review of the Literature. 61
30956700 2019
44
Metanephric mesenchyme-derived Foxd1+ mesangial precursor cells alleviate mesangial proliferative glomerulonephritis. 61
30810761 2019
45
IgA-Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits. 61
30611830 2019
46
Pauci-immune proliferative glomerulonephritis and fungal endocarditis: More than a mere coincidence? 61
30846459 2019
47
Plasma sMer, sAxl and GAS6 levels correlate with disease activity and severity in lupus nephritis. 61
30588607 2019
48
Histological spectrum of renal disease in HIV/AIDS patients with significant proteinuria: An Indian perspective. 61
31041214 2019
49
Complete biopsy-proven resolution of deposits in recurrent proliferative glomerulonephritis with monoclonal IgG deposits (PGNMIGD) following rituximab treatment in renal allograft. 61
30764798 2019
50
Corticosteroid therapy alone for the treatment of C3 glomerulonephritis in association with monoclonal gammopathy
. 61
30474593 2019

Variations for Proliferative Glomerulonephritis

Expression for Proliferative Glomerulonephritis

Search GEO for disease gene expression data for Proliferative Glomerulonephritis.

Pathways for Proliferative Glomerulonephritis

Pathways related to Proliferative Glomerulonephritis according to GeneCards Suite gene sharing:

(show all 43)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 SIGLEC1 MPO IL6 IL4 IFNG CXCL10
2
Show member pathways
13.75 TGFB1I1 PDGFD IL6 IL4 CXCR3 CXCL9
3
Show member pathways
13.65 IL6 IL4 IFNG EDN1 CXCR3 CXCL9
4
Show member pathways
13.57 EDN1 CXCR3 CXCL9 CXCL10 CD55 CCR5
5
Show member pathways
13.33 IL6 IL4 IFNG CXCL10 CCR5 CCR1
6
Show member pathways
13.25 PDGFD IL6 IL4 CXCR3 CXCL9 CXCL10
7
Show member pathways
13.13 PDGFD IL6 IL4 CXCR3 CXCL9 CXCL10
8
Show member pathways
13.1 IL6 IFNG CXCL9 CXCL10 CCL2 C3
9
Show member pathways
12.84 IL6 IL4 IFNG CXCL9 CD55 C3
10
Show member pathways
12.81 TGFB1I1 CXCR3 CXCL9 CXCL10 CCR5 CCR1
11
Show member pathways
12.59 MPO IL6 IFNG CXCL9 CCL2
12 12.55 MPO IL4 IFNG CXCL10 CCL2
13
Show member pathways
12.3 IL6 IL4 IFNG CXCL10 CCL2
14
Show member pathways
12.29 MPO IL6 IL4 IFNG CCL2
15
Show member pathways
12.27 PDGFD IL6 IL4 IFNG CCN2
16 12.23 IL6 IFNG CR1 C3
17
Show member pathways
12.2 IL4 IFNG CR1 CCR5 C3
18
Show member pathways
12.18 IL6 IL4 IFNG CXCL10
19
Show member pathways
12.11 CR1 CFH CD55 C3
20 12.11 CR1 CFH CD55 C3
21
Show member pathways
12.07 CR1 CFH CD55 C3
22
Show member pathways
12.03 IL6 CXCR3 CXCL9 CXCL10 CCR5 CCR1
23 11.96 IL6 EDN1 CXCL10 CCL2
24
Show member pathways
11.92 CR1 CFH CD55 C3
25 11.91 IL6 IL4 IFNG CXCL10 CCL2
26 11.9 IL6 IFNG CCR5 CCR1
27 11.88 IL6 IL4 CR1 CD55
28 11.83 IL6 IFNG CCL2
29 11.8 THY1 MPO IL6 IL4 IFNG CCR1
30 11.77 IL6 IL4 IFNG
31 11.75 THY1 IL4 IFNG CXCR3
32 11.72 THY1 IL6 IFNG
33 11.6 IL6 CR1 C3
34 11.52 IL6 IL4 EDN1 CCN2 CCL2
35 11.48 IL6 IFNG CR1 CCL2
36 11.44 THY1 MPO IL6 CCN2
37 11.38 IFNG CXCL9 CXCL10
38 11.34 CXCR3 CXCL9 CXCL10
39 11.3 IL6 IL4 IFNG
40 11.28 IL6 IL4 IFNG CXCL9 CXCL10 CCL2
41 11.24 IL6 IL4 IFNG
42 10.94 PDGFD IL6 IL4 CXCL9 CXCL10 CCN2
43 10.79 IL6 IL4 CXCL10 CCR5 CCR1 CCL2

GO Terms for Proliferative Glomerulonephritis

Cellular components related to Proliferative Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.93 PDGFD MPO IL6 IL4 IFNG EDN1
2 cell surface GO:0009986 9.8 THY1 CXCR3 CR1 CD55 CCR5 C3
3 external side of plasma membrane GO:0009897 9.73 THY1 CXCR3 CXCL9 CXCL10 CCR5 CCR1
4 cell GO:0005623 9.7 THY1 MPO IL6 EDN1 CXCR3 CXCL9
5 extracellular region GO:0005576 9.5 THY1 SIGLEC1 PDGFD MPO IL6 IL4

Biological processes related to Proliferative Glomerulonephritis according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.26 IL6 IL4 CXCR3 CXCL9 CXCL10 CCR5
2 G protein-coupled receptor signaling pathway GO:0007186 10.16 EDN1 CXCR3 CXCL9 CXCL10 CCR5 CCR1
3 positive regulation of cell proliferation GO:0008284 10.05 PDGFD IL6 IFNG EDN1 CXCL10 CCN2
4 cell adhesion GO:0007155 10.04 THY1 TGFB1I1 SIGLEC1 CXCR3 CCR1 CCN2
5 positive regulation of cell migration GO:0030335 9.96 PDGFD EDN1 CXCL10 CCR1
6 angiogenesis GO:0001525 9.96 THY1 CXCR3 CCN2 CCL2
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.94 PDGFD CCR1 CCN2 CCL2
8 defense response to virus GO:0051607 9.94 IL6 IFNG CXCL9 CXCL10
9 cytokine-mediated signaling pathway GO:0019221 9.91 IL6 IL4 CXCL10 CCR5 CCR1 CCL2
10 defense response GO:0006952 9.89 MPO CXCL9 CXCL10 CCR5
11 cellular response to lipopolysaccharide GO:0071222 9.88 IL6 CXCL9 CXCL10 CCR5 CCL2
12 cell-cell signaling GO:0007267 9.88 THY1 EDN1 CXCL9 CXCL10 CCR5 CCR1
13 regulation of complement activation GO:0030449 9.87 CR1 CFH CD55 C3
14 positive regulation of cytosolic calcium ion concentration GO:0007204 9.85 EDN1 CXCR3 CD55 CCR5 CCR1
15 response to bacterium GO:0009617 9.84 CXCL9 CXCL10 CCL2 C3
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 IL6 IL4 IFNG
17 neutrophil chemotaxis GO:0030593 9.83 EDN1 CXCL9 CXCL10 CCL2
18 positive regulation of smooth muscle cell proliferation GO:0048661 9.81 PDGFD IL6 EDN1
19 calcium-mediated signaling GO:0019722 9.81 EDN1 CXCR3 CCR5 CCR1
20 chemotaxis GO:0006935 9.8 CXCR3 CXCL9 CXCL10 CCR5 CCR1 CCL2
21 cell surface receptor signaling pathway GO:0007166 9.8 IFNG EDN1 CXCR3 CXCL10 CCR5 CCR1
22 humoral immune response GO:0006959 9.79 IL6 IFNG CCL2
23 cell chemotaxis GO:0060326 9.77 CXCR3 CXCL10 CCR5 CCR1 CCL2
24 positive regulation of release of sequestered calcium ion into cytosol GO:0051281 9.72 THY1 CXCL9 CXCL10
25 complement activation, alternative pathway GO:0006957 9.67 CFH C3
26 T cell chemotaxis GO:0010818 9.67 CXCR3 CXCL10
27 positive regulation of MHC class II biosynthetic process GO:0045348 9.65 IL4 IFNG
28 positive regulation of receptor biosynthetic process GO:0010870 9.65 IFNG EDN1
29 positive regulation of NMDA glutamate receptor activity GO:1904783 9.63 IFNG CCL2
30 chemokine-mediated signaling pathway GO:0070098 9.63 CXCR3 CXCL9 CXCL10 CCR5 CCR1 CCL2
31 regulation of complement-dependent cytotoxicity GO:1903659 9.62 CFH CD55
32 positive regulation of apoptotic cell clearance GO:2000427 9.61 CCL2 C3
33 inflammatory response GO:0006954 9.61 SIGLEC1 IL6 CXCR3 CXCL9 CXCL10 CCR5
34 neuroinflammatory response GO:0150076 9.6 IL4 IFNG
35 positive regulation of cellular respiration GO:1901857 9.58 IL4 IFNG
36 immune response GO:0006955 9.32 IL6 IL4 IFNG CXCR3 CXCL9 CXCL10

Molecular functions related to Proliferative Glomerulonephritis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.78 MPO CXCL10 CFH CCN2
2 growth factor activity GO:0008083 9.73 PDGFD IL6 IL4 CCN2
3 virus receptor activity GO:0001618 9.67 CR1 CD55 CCR5
4 chemokine activity GO:0008009 9.63 CXCL9 CXCL10 CCL2
5 chemokine binding GO:0019956 9.5 CXCR3 CCR5 CCR1
6 C-C chemokine binding GO:0019957 9.43 CXCR3 CCR5 CCR1
7 CXCR3 chemokine receptor binding GO:0048248 9.4 CXCL9 CXCL10
8 chemokine (C-C motif) ligand 5 binding GO:0071791 9.37 CCR5 CCR1
9 C-C chemokine receptor activity GO:0016493 9.33 CXCR3 CCR5 CCR1
10 cytokine activity GO:0005125 9.17 IL6 IL4 IFNG EDN1 CXCL9 CXCL10
11 chemokine receptor activity GO:0004950 9.13 CXCR3 CCR5 CCR1

Sources for Proliferative Glomerulonephritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....